It takes a specialist like Zurex Pharma to overcome the scientific and technical barriers to improved skin antisepsis – a critical component in the prevention of Surgical Site Infections (SSIs).   

Board of Directors

Frederick A. Robertson, M.D.

Chairman

 

Thomas V. Ressemann

Independent Director

 

Michael Liang, Ph.D.

Partner, Baird Capital

Robert B. Truitt

President and CEO, Ash

Access Technology

Scientific Advisory Board

Dr. Scott Anseth

Surgeon, Twin Cities Orthopedics

 

Dr. Charles E. Edmiston, Jr. Ph.D

Infection Prevention

Dr. Andrew Mulder

Surgeon, St. Cloud Orthopedics

Maureen Spencer, M.Ed, RN, CIC, FAPIC

Infection Prevention

Mayumi Verona, BSN, RN, CNOR

Dignity Health

Management

Paul Vajgrt

CEO

Andrew Morgan R.Ph.

Executive Vice President,

Regulatory Affairs

and Clinical

Alex M. Kasper

Chief Financial Officer